{"groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"FG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"FG001","title":"Bevacizumab Plus Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"145"},{"groupId":"FG001","numSubjects":"150"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal/Lost to follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"200"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"198"},{"comment":"There is one patient assigned in the BC arm who actually received ABC treatment. This patient is evaluated in the treatment arm to which he/she was randomly assigned (BC) for all the efficacy (Intention-to-Treat (ITT)) analyses. For the safety analysis the patient is evaluated according to the treatment he/she received (ABC treatment), irrespective of the allocated treatment at randomization.","groupId":"FG001","numSubjects":"200"}],"type":"Received at least one dose of trial treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"4"}],"comment":"Patients who were on treatment at database cut-off for final efficacy analysis: September 01, 2023","type":"On treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"192"},{"groupId":"FG001","numSubjects":"196"}],"comment":"Atezolizumab plus bevacizumab plus chemotherapy: 109 progressions, 62 toxicities, 9 deaths, 7 investigator decisions, 1 patient decision, 2 other; Bevacizumab plus chemotherapy: 141 progressions, 35 toxicities, 9 deaths, 1 investigator decision, 2 patient decisions, 8 other","type":"Treatment failures"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Never started treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"48"}],"comment":"Patients who were on follow-up at database cut-off for final efficacy analysis: September 01, 2023","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"149"},{"groupId":"FG001","numSubjects":"152"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}